ATHE 0001213900-25-113847 6-K Filing: Nov 24, 2025

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM6-K

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-163

UNDERTHE SECURITIES EXCHANGE ACT OF 1934

Forthe month of November 24, 2025

AlterityTherapeutics Limited

(Name of Registrant)

Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073,333-248980 and 333-228671)and our Registration Statements on Form F-3 (Files No. 333-274816,333-251647, 333-231417and 333-250076)

ALTERITYTHERAPEUTICS LIMITED

(adevelopment stage enterprise)

The following exhibits are submitted:

99.1	Initial Director’s Interest Notice - Stamler

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Alterity Therapeutics Limited
By:	/s/ Julian Babarczy
	Julian Babarczy
	Chairman

Date: November 24, 2025

Exhibit 99.1

Appendix 3XInitial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity	Alterity Therapeutics Limited
ABN	37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19.A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	David Stamler
Date of appointment	21 November 2025

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities 11,688,312 - FULLY PAID ORDINARY SHARES 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028 40,000,200 - UNLISTED OPT EXP 21/03/2029 @ US$0.0030 91,392,720 - UNLISTED OPT EXP 06/01/2026 @ $0.0320 290,400,000 - UNLISTED OPT EXP 08/08/2030 @ US$0.0086

Part 2 - Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest<br><br> <br><br><br> <br>Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	133,333 - AMERICAN DEPOSITARY SHARES<br><br> (equivalent to 79,999,800 FULLY PAID ORDINARY SHARES)

Part 3 - Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
---	---
No. and class of securities to which interest relates	N/A

See chapter 19 for defined terms.

Appendix 3X Page 1

11/03/2002

ATHE 6-K